United Therapeutics Corporation Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years
United Therapeutics Corporation (UTHR) had Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years of $24.40 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Expected Future Benefit Payment
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter · last filed 2026-02-25
- 2025-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $24.40M.
- 2024-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $20.20M.
- 2023-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $19.30M.
- 2022-12-31: Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years $30.10M.
| Period end | Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years |
|---|---|
| 2025-12-31 | $24.40M 10-K · filed 2026-02-25 |
| 2024-12-31 | $20.20M 10-K · filed 2025-02-26 |
| 2023-12-31 | $19.30M 10-K · filed 2024-02-21 |
| 2022-12-31 | $30.10M 10-K · filed 2023-02-22 |
| 2021-12-31 | $38.90M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |